Editing Lipid-lowering agent (section)

==Research==
Investigational classes of hypolipidemic agents:
* [[CETP inhibitor]]s (cholesteryl ester transfer protein), 1 candidate is in trials. ([[Anacetrapib]]) It is expected that these drugs will mainly increase HDL while lowering LDL
* [[Squalene synthase inhibitor]]
* [[ApoA-1 Milano]]
* Succinobucol (AGI-1067), a novel antioxidant, failed a phase-III trial.
* Apoprotein-B inhibitor [[mipomersen]] (approved by the FDA in 2013 homozygous [[familial hypercholesterolemia]].<ref>Pollack, Andrew (29 January 2013) [https://www.nytimes.com/2013/01/30/business/fda-approves-genetic-drug-to-treat-rare-disease.html F.D.A. Approves Genetic Drug to Treat Rare Disease] The New York Times, Retrieved 31 January 2013</ref><ref>Staff (29 January 2013) [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder] U.S. Food and Drug Administration, Retrieved 31 January 2013</ref>).
* [[Bempedoic acid]], an ATP citrate lyase inhibitor